New Horizons in Brain Cancer Treatment: Collaboration between Neurosurgery and Immunotherapy
Brain cancer is a serious challenge in modern medicine and has one of the lowest survival rates of all cancers. In 2019 alone, brain cancer was diagnosed in over 350 thousand people worldwide, and incidence of the disease has been increasing ever since. Therefore, the search for innovative approaches and techniques to improve patient prognosis…
Professor Renz visited the Biotherapy Clinic in Israel
In July 2023, Prof. Wolfgang Renz visited the Biotherapy International clinic in Israel, as part of a business and friendly visit. Professor Renz has been a partner of Biotherapy International in Germany since 2015, where he heads the Center for Complementary Medicine. During his visit, details of joint cooperation and plans for further development of…
Revolutionizing Cancer Treatment: Intentionally Mismatched Donor Cell Immunotherapy
After over thirty years of dedicated research, Prof. Slavin and the Biotherapy International team recently published groundbreaking findings in the Journal of Cancer Research and Clinical Oncology, showcasing the success of their pioneering immunotherapy approach. This innovative method involves using intentionally mismatched donor lymphocytes, activated before administration, for anti-cancer immunotherapy. The study addresses the urgent…
Leading physicians from Kazakhstan visited Israel
In June 2022 and following an invitation by Prof. Shimon Slavin, the Biotherapy International Clinic in Tel Aviv recently welcomed specialists from Kazakhstan: oncologist Daniyar Dzhumatayev, surgeon Askhat Ibambetov, and radiologist Ruslan Panov. The doctors that made up the delegation all practice in medical centers in Almaty, and have been cooperating with the clinic for…
Prof. Slavin and HepC Therapeutics are researching new viral-based treatments for COVID-19
Prof. Slavin is now serving as the medical director of HepC Therapeutics, Budapest, Hungary in partnership with ProBioGen, Berlin, Germany is now involved in clinical application of another poultry virus for treatment of COVID-19. This new virus, an attenuated infectious bursal disease virus (IBDV) for post-exposure treatment of patients infected with SARS-CoV-2 can be applied…
New medicinal product that harnesses the therapeutic potential of MSC-derived exosomes
After gaining clinical experience using bone marrow, placenta and cord tissue-derived mesenchymal stromal cells (MSCs), as well as the cumulative experience of more than 500 patients for over 10 years, we decided to investigate the potential therapeutic effects of MSCs’ excretory exosomes. These contain many of the therapeutic components that exist in MSCs, especially microRNAs,…
Prof. Slavin and his team have recently discovered a new oncolytic virus derived from chicken’s Newcastle disease virus (NDV)
Professor Slavin and his team have recently made a groundbreaking discovery: a novel oncolytic virus derived from the Newcastle disease virus (NDV) found in chickens. While NDV poses a threat to poultry, it is harmless to humans. Various members of the NDV family have been used in clinical practice for many years, demonstrating its potential…